<DOC>
	<DOCNO>NCT00945191</DOCNO>
	<brief_summary>This trial see effect combination therapy CS-1008 Paclitaxel/Carboplatin patient 's response locally advance metastatic ovarian cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With CS-1008 Treat Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm , epithelial carcinoma ovary primary peritoneal carcinoma ( FIGO Stage IIIC IV ) . ( Subjects follow histologic epithelial cell type eligible study : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma otherwise specify . ) Enrollment within 6 week surgical resection ( debulking ) . Residual tumor mass &gt; 1 cm objectively measurable/evaluable disease define RECIST criterion . No prior therapy ovarian cancer ( ie , chemotherapy radiotherapy [ RT ] abdomen pelvis ) surgical debulking disease . At least 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Adequate organ bone marrow function evidence : Absolute neutrophil count ≥ 1,500/µL ( equivalent NCI CTCAE , Version 3.0 grade 1 ) Platelet count ≥ 100,000/µL ( CTCAE grade 0 1 ) Hemoglobin ≥ 9 g/dL Serum creatinine ≤ 1.5 x institutional ULN ( CTCAE grade 1 ) Bilirubin ≤ 1.5 x ULN ( CTCAE grade 1 ) AST alkaline phosphatase ≤ 2.5 x ULN ( CTCAE grade 1 ) Adequate neurologic function ( ie , sensory motor neuropathy ≤ CTCAE grade 1 ) . Women childbearing potential must willing consent use effective contraception treatment 3 month thereafter . All subject childbearing potential must negative pregnancy test ( serum urine ) result ≤ 72 hour initiate study treatment . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IRBapproved ICF performance studyspecific procedure test . Prior invasive malignant disease within 5 year except squamous cell basal cell carcinoma . Current diagnosis borderline epithelial ovarian tumor ( formerly `` tumor low malignant potential '' ) recurrent ovarian epithelial cancer . Positive human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) potential additional toxicity treatment regimen . Anticipation need major surgical procedure RT study . History follow condition within 6 month study enrollment : myocardial infarction ; severe/unstable angina pectoris ; coronary/peripheral artery bypass graft ; New York Heart Association ( NYHA ) class III IV congestive heart failure ; cerebrovascular accident transient ischemic attack , pulmonary embolism , clinically significant thromboembolic event ; clinically significant pulmonary disease ( eg , severe chronic obstructive pulmonary disease asthma ) . Clinically active brain metastasis ( ie , untreated , still require therapy steroid RT , progression within 4 week completion RT ) ; uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis . Pregnant lactating . Prior treatment CS1008 , agonistic DR5 antibody , TRAIL . Known history hypersensitivity reaction component CS1008 , paclitaxel ( docetaxel ) , carboplatin formulation . Serious intercurrent medical psychiatric illness condition opinion Investigator would impair ability give inform consent unacceptably reduce protocol compliance safety study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally</keyword>
	<keyword>advanced</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>neoplasm</keyword>
</DOC>